Alan I. So
Dr. So’s current research focuses on the study of development of novel therapeutics for bladder cancer and determination of the functional role of GLI1/2 in the progression of prostate cancer to its lethal stage of androgen independence. He has characterized the functional role of different survival genes (including clusterin and Hsp27) in different tumor models (prostate, breast, lung, and bladder) in cancer progression. His current research focuses on discovery and development of novel agents to treat bladder cancer as well as development of the mechanisms of treatment resistance in renal cell carcinoma.